Epigenetic Clock for Skin and Blood Cells Applied to Hutchinson Gilford Progeria Syndrome and Ex Vivo Studies.

Steve Horvath,Junko Oshima,George M. Martin,Ake T. Lu,Austin Quach,Howard Cohen,Sarah Felton,Mieko Matsuyama,Donna Lowe,Sylwia Kabacik,James G. Wilson,Alex P. Reiner,Anna Maierhofer,Julia Flunkert,Abraham Aviv,Lifang Hou,Andrea A. Baccarelli,Yun Li,James D. Stewart,Eric A. Whitsel,Luigi Ferrucci,Shigemi Matsuyama,Kenneth Raj
DOI: https://doi.org/10.18632/aging.101508
2018-01-01
Abstract:DNA methylation (DNAm)-based biomarkers of aging have been developed for many tissues and organs. However, these biomarkers have sub-optimal accuracy in fibroblasts and other cell types used in ex vivo studies. To address this challenge, we developed a novel and highly robust DNAm age estimator (based on 391 CpGs) for human fibroblasts, keratinocytes, buccal cells, endothelial cells, lymphoblastoid cells, skin, blood, and saliva samples. High age correlations can also be observed in sorted neurons, glia, brain, liver, and even bone samples. Gestational age correlates with DNAm age in cord blood. When used on fibroblasts from Hutchinson Gilford Progeria Syndrome patients, this age estimator (referred to as the skin & blood clock) uncovered an epigenetic age acceleration with a magnitude that is below the sensitivity levels of other DNAm-based biomarkers. Furthermore, this highly sensitive age estimator accurately tracked the dynamic aging of cells cultured ex vivo and revealed that their proliferation is accompanied by a steady increase in epigenetic age. The skin & blood clock predicts lifespan and it relates to many age-related conditions. Overall, this biomarker is expected to become useful for forensic applications (e.g. blood or buccal swabs) and for a quantitative ex vivo human cell aging assay.
What problem does this paper attempt to address?